Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
613
datasets available to search
ShareScore release 0.9.0
Dataset results
613 results for “Dengue”
Indexes of Virstrain for FMDV and Dengue
<p>Version 0.1</p>
Flow chart on the selection of patients with positive serological tests for dengue in the 20 regions of the country during the period 2016 - 2022.
Open the record for dataset details and reuse information.
A spatial autocorrelation analysis of environmental factors related to Dengue using Moran's I spatial statistics: A study from Nepal 2020-2023
Open the record for dataset details and reuse information.
Coagulation abnormalities in dengue fever infection: a systematic review and meta-analysis
<p><b>Background:</b> Coagulation mechanisms are reported to be affected in dengue illness and evidenced by prolonged activated partial thromboplastin time (APTT) and prothrombin time (PT). The main aim of this systematic review and meta-analysis is to determine the magnitude of coagulation abnormalities among patients with dengue fever infection.</p> <p><b>Method:</b> This systematic review and meta-analysis were conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The Joana Brigg's Institute (JBI) critical appraisal checklist was used for quality appraisal. STATA version 11 software was used for meta-analysis. The magnitude of coagulation abnormalities among dengue fever patients was determined by using a random-effects model. Subgroup and sensitivity analysis were performed to investigate the possible source of heterogeneity. Egger weighted regression tests were used to check the presence of publication bias among the included articles.</p> <p><b>Result: </b>Forty-two studies with a total of 12,221 dengue fever patients were eligible for meta-analysis in this study. Of which 22, 15, and 26 studies were used to determine the magnitude of prolonged APTT, PT, and thrombocytopenia, respectively. The magnitude of prolonged APTT and PT among patients with dengue fever infection were 42.91% (95% CI: 30.95, 54.87) I<sup>2</sup> = 99.1% and 16.48% (95% CI: 10.95, 22.01) I<sup>2</sup>=97.0%, respectively. Besides, the magnitude of thrombocytopenia among dengue fever patients was 70.29% (95% CI: 62.69, 77.89) I<sup>2</sup>=99.3%. The magnitude of prolonged APTT in children and adults was 51.21% (95% CI: 24.54, 77.89) and 44.89% (95% CI: 28.32, 61.45), respectively. Similarly, the overall magnitude of prolonged PT in children and adults were 13.40% (95% CI: 6.09, 20.71) and 18.73% (95% CI: 7.49, 29.96), respectively.</p> <p><b>Conclusion: </b>The result of this study showed that there is a high magnitude of prolonged APTT and PT in dengue fever patients. Therefore, screening and early correction of coagulation abnormalities may be helpful to reduce further complications in those patients.</p>
Fig. 5 in Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease
Fig. 5. Chemical structures of gedunin (7).
Fig. 10 in Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease
Fig. 10. Chemical structures of (a) Melatonin (40) and (b) the benzofuranone derivative (41).
Fig. 6 in Recent advances in natural products as potential inhibitors of dengue virus with a special emphasis on NS2b/NS3 protease
Fig. 6. Chemical structures of (a) andrographolide (8) and (b) stachyonic acid A (9).
Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)
ClinicalTrials.gov study NCT01477580. IPD Sharing: YES. Countries: 0. Publications: 3.
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
ClinicalTrials.gov study NCT06741683. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease
ClinicalTrials.gov study NCT06843226. IPD Sharing: YES. Countries: 1. Publications: 0.
Dengue Serostatus Study in the Philippines
ClinicalTrials.gov study NCT03465254. IPD Sharing: UNDECIDED. Countries: 0. Publications: 1.
A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers
ClinicalTrials.gov study NCT06665035. IPD Sharing: YES. Countries: 2. Publications: 0.
A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus
ClinicalTrials.gov study NCT04935801. IPD Sharing: YES. Countries: 1. Publications: 0.
Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy
ClinicalTrials.gov study NCT04023708. IPD Sharing: YES. Countries: 1. Publications: 0.
Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
ClinicalTrials.gov study NCT05268302. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
ClinicalTrials.gov study NCT04113330. IPD Sharing: YES. Countries: 1. Publications: 0.
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
ClinicalTrials.gov study NCT01542632. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of AT-752 in Patients With Dengue Infection
ClinicalTrials.gov study NCT05466240. IPD Sharing: Not stated. Countries: 10. Publications: 0.
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
ClinicalTrials.gov study NCT06579755. IPD Sharing: YES. Countries: 4. Publications: 0.
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
ClinicalTrials.gov study NCT05507450. IPD Sharing: YES. Countries: 7. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.